For Novo Nordisk, a company still rooted in principles ... especially as biosimilar versions of Sanofi’s Lantus are now gaining ground in Europe and the US. Later this month the company will ...
The FDA has approved Novo Nordisk’s Xultophy and Sanofi’s Soliqua ... while Soliqua (formerly known as LixiLan) combines Lantus with Adlyxin (Lxyumia outside the US). Both 2-in-1 once daily ...
injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...
The Associated Press on MSN4d
Newsom committed California to making its own insulin. It’s a year behind his scheduleGov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback